fertility-health
Thyroid Disorders and Fertility: How Hypothyroidism and Hyperthyroidism Affect Conception
Dr. Carolina Gallardo
Unexplained Infertility
A normal fertility workup does not mean nothing is wrong — it means current tests cannot detect the specific cause, and effective treatments still exist.
Diagnosed in 15–30% of infertile couples after standard evaluation
Defined as failure to conceive after ≥12 months of regular unprotected intercourse with normal standard workupStandard workup includes: semen analysis, ovarian reserve testing (AMH, AFC), tubal patency (HSG), and documentation of ovulationPotential underlying mechanisms include subtle egg quality issues, fertilization failure, implantation dysfunction, or sperm-egg interaction defects not captured by standard testsPrognosis is generally favorable: cumulative live birth rates with expectant management reach 30–50% at 3 years for couples under 35 (Collins et al., NEJM 1983)Empirical treatment with letrozole + IUI or IVF is effective even without a defined diagnosis
Find Clinics That Specialize in Unexplained InfertilityHow Unexplained Infertility Affects Fertility
Unexplained infertility is, by definition, a diagnosis of exclusion: ovulation is confirmed, fallopian tubes are patent on hysterosalpingogram (HSG), the uterine cavity is normal, and semen analysis is within reference range. Yet conception does not occur. The label reflects the limitations of our current diagnostic toolkit rather than an absence of pathology. Emerging evidence points to several sub-clinical mechanisms that standard tests miss: minor egg quality deficits not reflected in antral follicle count or AMH, sperm DNA fragmentation above the fertilization-impairing threshold in otherwise normal semen analyses, subtle endometrial receptivity abnormalities (altered integrin expression, immune cell dysfunction), and embryonic chromosomal abnormalities that result in failed implantation or early undetected pregnancy loss.
Mild endometriosis is frequently found at laparoscopy in women with unexplained infertility — studies suggest 20–40% of such patients have Stage I–II peritoneal endometriosis not visible on imaging (Meuleman et al., Hum Reprod 2009). Similarly, subclinical thyroid dysfunction, antiphospholipid antibodies, and natural killer cell abnormalities are debated contributors that some reproductive immunologists investigate in recurrent implantation failure. However, routine expanded immune testing is not endorsed by ASRM guidelines outside of clinical research settings, given insufficient evidence for treatment efficacy.
The critical clinical distinction in unexplained infertility is age. Couples under 35 with <2 years of trying have substantial spontaneous conception potential — the NEJM-published "Hunault model" estimates cumulative pregnancy rates of 35–46% over 12 months of continued expectant management in favorable-prognosis unexplained infertility. For women 35–37, the window for expectant management narrows to 6 months. At 38 and older, empirical treatment should begin promptly given exponential age-related declines in egg quality. The therapeutic sequence — from expectant management through IUI to IVF — should be calibrated to the couple's specific age, duration of infertility, and emotional readiness.
Treatment Options
Treatment is individualized based on age, severity, duration of infertility, and partner factors. Work with your reproductive endocrinologist to determine the right sequence for your specific situation.
First-line treatment
Expectant Management (Watchful Waiting)
For couples under 35 with fewer than 2 years of trying and no other concerning features, expectant management with lifestyle optimization is a legitimate first approach. Cumulative live birth rates with expectant management are 30–50% at 3 years (Collins et al., NEJM 1983). This avoids unnecessary intervention and associated costs and risks. ASRM recommends against immediate empirical treatment in young couples with favorable prognosis unexplained infertility. Optimizing timing (LH surge testing, mid-cycle ultrasound) and lifestyle factors should accompany this approach.
Typical success rate
30–50% cumulative live birth rate at 3 years (age < 35, favorable prognosis)
First-line treatment
Letrozole + IUI
Letrozole (2.5–5 mg on cycle days 2–6) stimulates mono- or bifollicular development, increasing the number of eggs available for fertilization in a given cycle, while IUI delivers sperm to the uterine cavity at the optimal time. The FASTT trial (Diamond et al., NEJM 2010) found that an accelerated treatment protocol beginning with IVF after 3 failed clomiphene+IUI cycles was more cost-effective than sequential escalation, but letrozole+IUI remains a standard first-line ART step. ASRM endorses 3–6 cycles before escalation to IVF.
Typical success rate
8–15% per cycle; cumulative 35–50% over 3–6 cycles (age < 38)
Clomiphene Citrate + IUI
Clomiphene (50–100 mg on days 2–6) with IUI was the historical standard first-line empirical treatment for unexplained infertility. It is slightly less effective than letrozole for ovulation induction and carries a higher multiple pregnancy rate (~8% twins). The FASTT trial established that moving to IVF after 3 clomiphene+IUI cycles is more cost-effective than continuing IUI with gonadotropins. Clomiphene+IUI may be considered when letrozole is unavailable or cost is a limiting factor.
Typical success rate
7–12% per cycle; cumulative 28–40% over 3–6 cycles
Gonadotropins + IUI
Injectable FSH with IUI achieves higher per-cycle pregnancy rates than oral agents (~15–20% per cycle in unexplained infertility) but carries significant multiple pregnancy risk (20–30% twin rate; 5% higher-order multiple risk). Given the OHSS and multiple pregnancy risks, ASRM recommends this combination only when oral agents have failed and the patient is not yet ready for IVF, or as a bridge. Careful monitoring with ultrasound is required. The elevated multiple pregnancy risk makes IVF with single embryo transfer (SET) a compelling alternative.
Typical success rate
15–20% per cycle; higher multiple pregnancy rate than oral agents
IVF (In Vitro Fertilization)
IVF directly addresses multiple potential mechanisms of unexplained infertility simultaneously: it retrieves multiple eggs, fertilizes them in a controlled laboratory environment, allows embryo selection (including preimplantation genetic testing for aneuploidy — PGT-A), and transfers a euploid embryo to a prepared endometrium. IVF also serves a diagnostic function — fertilization failure or poor embryo development in vitro reveals sub-clinical egg or sperm quality problems not apparent from standard tests. For women 38 and older with unexplained infertility, moving to IVF sooner rather than later is generally recommended. The FASTT trial supports IVF as the most cost-effective treatment for unexplained infertility after 3 failed IUI cycles.
Typical success rate
40–55% live birth rate per embryo transfer for women under 35 (SART 2022)
IVF with PGT-A (Preimplantation Genetic Testing)
PGT-A involves biopsying a trophectoderm cell from a day-5 blastocyst and testing for chromosomal aneuploidy. Transferring a confirmed euploid embryo achieves implantation rates of 60–70% per transfer, dramatically higher than untested embryos. For women with unexplained infertility and recurrent IVF failure or recurrent pregnancy loss, PGT-A may identify that embryonic chromosomal abnormalities are the primary cause. ASRM notes that PGT-A benefit is most clearly demonstrated for women 38 and older and for those with recurrent IVF failure.
Typical success rate
60–70% implantation rate per euploid embryo transfer; live birth rate ~50–65% under 38 (SART 2022)
What Patients with Unexplained Infertility Can Expect
Unexplained infertility generally carries a favorable prognosis compared to structural or severe hormonal causes — the standard fertility workup is normal, which means the reproductive machinery is intact. Age is the most powerful predictor of outcome: IVF success rates in unexplained infertility patients under 35 are among the highest of any diagnostic category. The challenge is calibrating when to escalate treatment versus allowing time for spontaneous conception.
| Treatment | Typical Success Range |
|---|---|
| Expectant management (age < 35, < 2 years) | 30–50% cumulative at 3 years |
| Letrozole + IUI | 8–15% per cycle; 35–50% cumulative over 3–6 cycles |
| Clomiphene + IUI | 7–12% per cycle; 28–40% cumulative |
| Gonadotropins + IUI | 15–20% per cycle |
| IVF (age < 35) | 40–55% live birth per transfer |
| IVF (age 35–37) | 30–40% live birth per transfer |
| IVF + PGT-A (euploid transfer) | 50–70% live birth per euploid transfer |
Individual outcomes vary significantly based on age, ovarian reserve, partner factors, and clinic expertise. These figures are based on published research (ASRM, SART, Cochrane Reviews) and national averages — they are not guarantees. Ask your clinic for their own reported outcomes for your specific diagnosis and age group.
Questions to Ask Your Reproductive Endocrinologist
Bring this list to your first consultation to make the most of your appointment.
- 1
Has my workup been complete — including both HSG (or saline sonogram) and ovarian reserve testing?
- 2
Should I be tested for sperm DNA fragmentation, even if the semen analysis is normal?
- 3
Given my age and how long we've been trying, do you recommend starting treatment now or continuing to try naturally?
- 4
Is letrozole + IUI the right first step for us, or should we move directly to IVF?
- 5
How many IUI cycles do you recommend before escalating to IVF?
- 6
Would you recommend PGT-A with IVF given my situation, and what is the expected benefit?
- 7
Should I have a diagnostic laparoscopy to rule out Stage I–II endometriosis?
- 8
If IVF reveals fertilization failure or poor embryo development, what would that tell us about the cause of our infertility?
When to See a Specialist
Couples with unexplained infertility should see a reproductive endocrinologist after 12 months of trying (age < 35), 6 months (age 35–37), or 3 months (age ≥ 38). If two or more pregnancy losses have occurred alongside difficulty conceiving, a recurrent pregnancy loss evaluation should be added to the infertility workup — see a specialist promptly rather than waiting the standard interval.
Ready to Find a Clinic That Specializes in Unexplained Infertility?
Look for clinics with reproductive endocrinologists (REs) who have documented experience treating Unexplained Infertility. Ask about their specific outcomes for your diagnosis and age group during your first consultation — outcomes vary significantly by clinic.
Select your state to browse fertility clinics near you:
Related Articles
IVF
Beta hCG After IVF: What Your First Result Means
Your first beta hCG result after IVF is one of the most nerve-wracking numbers in the entire process. This guide explains what it means, what doubling times to expect, how to interpret a borderline result, and what comes next.
Dr. Hannah Ní Bhriain Russell
IVF
OHSS After IVF: Symptoms, Classification, Prevention & Treatment
Ovarian hyperstimulation syndrome is the most serious complication of IVF stimulation. This guide covers who is at risk, how severity is graded, evidence-based prevention strategies, and what to do if symptoms develop.
Dr. Hannah Ní Bhriain Russell
IVF
ICI vs IUI vs IVF: Which Treatment Should You Start With?
The right starting point for fertility treatment is never the same for everyone — it depends entirely on your diagnosis. This guide gives you a clear, evidence-based framework for deciding between ICI, IUI, and IVF.
Prof. Jane Harries
Related Conditions
Polycystic Ovary Syndrome (PCOS)
Affects 1 in 10 women of reproductive age (6–12% globally)
Learn moreEndometriosis
Affects ~10% of reproductive-age women; up to 50% of infertile women
Learn moreMale Factor Infertility
Contributes to 40–50% of all infertility cases; sole cause in ~20% of couples
Learn more